XERS · NASDAQ
Xeris Biopharma Holdings (XERS) Stock Price & Fundamentals
Xeris Biopharma Holdings (XERS) closed at $699.89 on Oct 9, 2026, up 0.85% from the previous close of $693.96.
Share price, past year
1Y +3.06%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $699.89 |
| Sep 30, 2026 | $682.65 |
| Aug 31, 2026 | $652.94 |
| Jul 31, 2026 | $648.56 |
| Jun 30, 2026 | $630.08 |
| May 29, 2026 | $653.27 |
| Apr 30, 2026 | $628.52 |
| Mar 31, 2026 | $653.09 |
| Feb 27, 2026 | $620.68 |
| Jan 30, 2026 | $639.52 |
| Dec 31, 2025 | $685.41 |
| Nov 28, 2025 | $700.49 |
| Oct 31, 2025 | $668.49 |
Key statistics
- Market cap
- $121.50B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.10
- Revenue (TTM)
- $335.41M
- Net income (TTM)
- −$17.17M
- Shares outstanding
- 173.6M
- Dividend yield
- —
- 52-week range
- $607.17 – $711.26
Xeris Biopharma Holdings's market cap is $121.50B, based on a share price of $699.89 and 173.6M shares outstanding as of Jun 30, 2026.
Financials
Xeris Biopharma Holdings reported revenue of $291.85M for fiscal 2025, up 43.72% from fiscal 2024.
Xeris Biopharma Holdings earned net income of $554.00K in fiscal 2025, a net margin of 0.2%.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $291.85M | +43.7% | $554.00K | 0.2% | $0.00 | — |
| FY2024ended Dec 31, 2024 | $203.07M | +23.9% | −$54.84M | −27.0% | −$0.37 | — |
| FY2023ended Dec 31, 2023 | $163.91M | +48.7% | −$62.26M | −38.0% | −$0.45 | — |
| FY2022ended Dec 31, 2022 | $110.25M | +122.3% | −$94.66M | −85.9% | −$0.70 | — |
| FY2021ended Dec 31, 2021 | $49.59M | +142.7% | −$122.73M | −247.5% | −$1.55 | −$96.62M |
| FY2020ended Dec 31, 2020 | $20.44M | — | −$91.14M | −446.0% | −$2.14 | −$80.94M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $92.10M | −$31.10M | −$0.18 |
| Q1 FY2026ended Mar 31, 2026 | $83.13M | $2.23M | $0.01 |
| Q4 FY2025ended Dec 31, 2025 | $85.81M | $11.08M | $0.07 |
| Q3 FY2025ended Sep 30, 2025 | $74.38M | $621.00K | $0.00 |
| Q2 FY2025ended Jun 30, 2025 | $71.54M | −$1.93M | −$0.01 |
| Q1 FY2025ended Mar 31, 2025 | $60.12M | −$9.22M | −$0.06 |
| Q4 FY2024ended Dec 31, 2024 | $60.10M | −$5.11M | −$0.02 |
| Q3 FY2024ended Sep 30, 2024 | $54.27M | −$15.74M | −$0.11 |
Company profile
- Name
- Xeris Biopharma Holdings, Inc.
- Ticker
- XERS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1375 West Fulton Street, Suite 1300, Chicago, IL 60607
- Fiscal year ends
- December
- SEC CIK
- 0001867096
Recent SEC filings
- Sep 9, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 17, 2026
- Jun 30, 2026
- Jun 11, 2026
- Jun 5, 2026
- May 7, 2026
Frequently asked questions
What is Xeris Biopharma Holdings's stock price?
Xeris Biopharma Holdings (XERS) closed at $699.89 on Oct 9, 2026, up 0.85% from the previous close of $693.96.
What is Xeris Biopharma Holdings's market cap?
Xeris Biopharma Holdings's market cap is $121.50B, based on a share price of $699.89 and 173.6M shares outstanding as of Jun 30, 2026.
How much revenue does Xeris Biopharma Holdings make?
Xeris Biopharma Holdings reported revenue of $291.85M for fiscal 2025, up 43.72% from fiscal 2024.
Does Xeris Biopharma Holdings pay a dividend?
Xeris Biopharma Holdings's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Xeris Biopharma Holdings, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures